Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Indivior Pharmaceuticals IncNASDAQ: INDV
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows in line with its trailing trend
Q2 FY2026 revenue of $343M rose 13.6% year over year, in line with the +13.5% change in trailing-twelve-month revenue. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +11.2% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $1.33B (+7.5%) for the fiscal year ending Dec 2026, a step up from the +4.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $343M+8.2% QoQ
- Last fiscal yearDec 2025
- $1.24B+4.3% YoY
- LTMJun 2026
- $1.33B+13.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.6% | +4.9% | -8.7 pp |
| 1 year | +4.3% | +7.5% | +3.2 pp |
| 3-year CAGR | +11.2% | +6.3% | -4.9 pp |
| 5-year CAGR | +4.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1.24B USD
- Year-over-year change
- +4.3%
- 4-year CAGR
- +11.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.24B | +4.3% |
| FY2024 | 2024-12-31 | 1.19B | +8.7% |
| FY2023 | 2023-12-31 | 1.09B | +21.3% |
| FY2022 | 2022-12-31 | 901M | +13.9% |
| FY2021 | 2021-12-31 | 791M | — |
Revenue vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's LTM Jun 2026 revenue of $1.33B is the 2nd highest of the 4 companies compared; the peer median is $830.44M.
- Its year-over-year change of +13.5% is the lowest of 4, against a peer median of +19.9%.
- Over three fiscal years its annual growth of +11.2% compares with a peer median of +9.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.75B | +15.3% | +9.9% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $1.33B | +13.5% | +11.2% |
| LTM Jun 2026 | $830.44M | +24.9% | +2.5% | |
| LTM Mar 2026 | $796.33M | +19.9% | +18.9% | |
| Peer median (excluding INDV) | $830.44M | +19.9% | +9.9% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 791M | 901M | 1.09B | 1.19B | 1.24B |
| Cost of Revenue | 127M | 151M | 174M | 231M | 246M |
| Gross Profit | 664M | 750M | 919M | 957M | 993M |
| Gross Margin | 83.9% | 83.2% | 84.1% | 80.6% | 80.1% |
| Research & Development | 52M | 74M | 116M | 107M | 97M |
| Selling, General & Admin | 431M | 469M | 569M | 618M | 634M |
| Operating Expenses | 451M | 831M | 1.08B | 925M | 728M |
| Depreciation & Amortization | 22M | 16M | 15M | 28M | 20M |
| EBITDA | 238M | (46M) | (99M) | 83M | 304M |
| EBITDA Margin | 30.1% | -5.1% | -9.1% | 7.0% | 24.5% |
| Operating Income | 213M | (81M) | (156M) | 32M | 265M |
| Operating Margin | 26.9% | -9.0% | -14.3% | 2.7% | 21.4% |
| Interest Income | 4M | 19M | 43M | 23M | 22M |
| Interest Expense | 26M | 29M | 35M | 41M | 45M |
| Other Income / Expenses | (23M) | (8M) | 7M | (18M) | (26M) |
| Income Before Tax | 190M | (89M) | (149M) | 14M | 239M |
| Pre-Tax Margin | 24.0% | -9.9% | -13.6% | 1.2% | 19.3% |
| Income Tax Expense | (15M) | (44M) | (20M) | 11M | 29M |
| Net Income | 205M | (44M) | (129M) | 2M | 210M |
| Net Margin | 25.9% | -4.9% | -11.8% | 0.2% | 16.9% |
| EPS (Basic) | 1.38 | (0.37) | (0.94) | 0.02 | 1.68 |
| EPS (Diluted) | 1.31 | (0.37) | (0.91) | 0.02 | 1.64 |
| Weighted Avg Shares | 145.66M | 139.01M | 137.31M | 132M | 125M |
| Weighted Avg Shares (Diluted) | 154.23M | 139.01M | 141.8M | 133M | 128M |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.